Introduction. Tumors invading the sacrum and/or ilium often represent incurable metastatic disease, and treatment is targeted toward palliation of symptoms and control of pain. As systemic opioid therapy is frequently inadequate and limited by side effects, a variety of interventional techniques are available to better optimize analgesia. Using six patients as a paradigm for interventional approaches to pain relief, we present a therapeutic algorithm for treating sacroiliac tumor-related pain in the oncologic population.
Introduction
Nonmalignant sacroiliac joint pain may result from inflammatory conditions secondary to joint instability, ligamentous laxity, shearing of the joint capsule, or arthropathies (e.g., pyogenic, crystal, or spondyloarthropathy) [1] . However, in oncologic patients, sacroiliitis is commonly multifactorial and may result from tumor burden, fracture, instability, and periosteal inflammation. It is also common to have increased pain following oncologic therapies including surgery and/or radiation. Tumor in the lateral sacrum or ilium may result in a similar constellation of symptoms as patients with nonmalignant sacroiliitis. Patients commonly present with focal gluteal pain radiating to the posterior thigh or sacrum [2] . While the pain symptoms may be similar to sacroiliac joint syndrome, we do not necessarily advocate stressing the joint to reproduce the pain [3] .
Initial conservative treatments for chronic nonmalignant sacroiliitis include anti-inflammatory analgesics and physical therapy [1] . More invasive measures such as sacroiliac joint steroid injections and denervation techniques can be considered if conservative measures are unsuccessful [4, 5] . However, a more aggressive treatment algorithm may be necessary in the oncologic patient with progressive sacral disease. While opioids, adjuvant analgesics, and bone strengthening medications are the usual pharmacologic mainstays for palliation of symptoms, practitioners should be more willing to pursue interventional measures such as denervation techniques and neuraxial implanted devices for malignant sacroiliac pain.
Numerous techniques are described for denervation of the sacroiliac joint usually following diagnostic blockade [6] . The majority of these techniques involve thermal coagulation (radiofrequency ablation [RFA] ) of nerves that innervate the sacroiliac joint. Common targets include the lateral branch of L4, dorsal ramus of L5, and the lateral branches of S1 to S3 [7] . The ablation is typically performed using large single conventional or cooled monopolar probes or bipolar strip lesioning techniques [1] . At our institution, we typically use a single needle conventional radiofrequency technique as this may be easier for oncologic patients to tolerate relative to other denervation practices. We describe patient cases and development of an algorithm for treatment of patients suffering from oncologic pain in the sacroiliac region.
Methods
The following case descriptions offer potential treatment paradigms for sacroiliac pain secondary to tumor invasion of the sacrum and/or ilium. We first describe six patients with metastatic sacroiliac joint pain. For each case, the progression of interventions is outlined. These include sacroiliac (SI) joint corticosteroid injection, diagnostic local anesthetic blocks leading to radiofrequency ablation (RFA) of the nerves innervating the SI joint, sacroplasty targeting lytic metastatic disease and associated insufficiency fractures, and implantable neuraxial devices such as intrathecal pump and dorsal column stimulator leads.
After describing six cases and their associated treatment paradigms, outcomes for 25 patients undergoing similar therapies with our treatment algorithm are provided.
Institutional review board approval was obtained for retrospective review of the collected data.
Case 1
Eighty-year-old male with history of stage IV lung adenocarcinoma with known metastasis to the spine including bilateral sacrum and ilium presented with a three-month history of worsening bilateral low back and buttock "dull aching" pain, without radiculopathy. He had completed radiation therapy, which did not resolve his pain. His initial numeric rating scale (NRS) pain score was 7/10, with the pain worse when walking and getting dressed. He was using twice-daily ibuprofen for the pain, which did not adequately control his symptoms, and had a strong desire to avoid opioids to minimize risk of cognitive side effects. He had significant tenderness to palpation at his SI joints bilaterally (Figure 1) . He elected to proceed with bilateral ultrasound-guided sacroiliac joint injections.
Case 2
Sixty-two-year-old male with history of stage IV prostate cancer with metastatic lesions (blastic metastasis) to the spine including the sacrum, status postradiation therapy and radium 223 infusion, presented with right-sided "achy" low back and buttock pain, worse with standing and walking, without radiculopathy of the buttocks ( Figure 2 ). His initial NRS pain score was a 10/10. His pain medication regimen consisted of methadone 20 mg every six hours with 30 mg before bed, immediaterelease oxycodone 60 mg every four hours as needed (he was using an average of six in 24 hours), gabapentin, and prednisone 5 mg daily. The patient did not have adequate pain relief and reported feeling excessively sedated to a degree that limited his ability to perform activities of daily living.
An initial diagnostic right-sided sacroiliac joint injection (under ultrasound guidance with 4 mL 0.25% bupivacaine and 40 mg triamcinolone, see technique for Case 1 below) was performed, which provided the patient with significant but transient relief of pain. He was able to stand and walk without much discomfort and was able to sleep comfortably through the night. However, this pain relief lasted less than a week and so he elected to proceed to a diagnostic lateral branch block and then RFA denervation of the sacroiliac joint.
Case 3
Fifty-eight-year-old male with history of metastatic renal cancer to the bone (lytic lesions), including bilateral sacrum and right posterior ilium, presented with worsening three-week history of right low back and buttock pain, without radicular symptoms ( Figure 3) . He was status postradiation therapy without resolution of his pain symptoms. His initial NRS pain score was 7-9/10. He did not find opioid medications helpful and was using high doses of NSAIDs for pain relief. He received a diagnostic sacroiliac joint injection with 3 mL of 0.25% bupivacaine, with total relief of his symptoms for only 24 hours. He proceeded to a diagnostic block and RFA denervation of the sacroiliac joint.
Case 4
Sixty-nine-year-old male with history of stage IV prostate cancer with known bony metastasis including the sacrum, status postradiation, presented with a four-week history of worsening right-sided buttock and lateral thigh pain. Pain was worse after walking only 12 steps, without radiculopathy into the lower extremities. CT scan demonstrated right iliac and sacral metastases with an associated sacral insufficiency fracture ( Figure 4A ). His initial NRS pain score was a 10/10. He did not tolerate oral opioid therapy and so was on high-dose NSAIDs, diazepam, and gabapentin without adequate pain relief. He underwent right-sided RFA denervation of the sacroiliac joint. He had near total relief of his symptoms for twelve hours, but return of symptoms thereafter. He elected to proceed to kyphoplasty-sacroplasty.
Case 5
Fifty-six-year-old male with history of metastatic renal cancer to the lungs and bones, including the sacrum and ilium, presented with a three-month history of worsening left buttock "throbbing" pain and left leg "shooting" pain. He had associated parasthesias in the left posterior aspect of his thigh and lateral leg. CT scan demonstrated a large left sacroiliac metastasis with impingement of the exiting sacral nerve roots ( Figure 5 ). He was status postradiation therapy without resolution of his pain symptoms. His initial NRS pain score was 7/10; however, he complained of excessive sedation on low-dose oxycodone therapy and did not report benefit from 600 mg of gabapentin three times a day. Given the CT scan findings and radicular symptoms, the patient underwent a caudal epidural steroid injection containing 40 mg of triamcinolone, 2 mL 1% lidocaine, and 3 mL 0.5% bupivacaine, from which he gained three days of complete pain relief but had return of symptoms thereafter. A diagnostic lateral branch block procedure was aborted due to obscured anatomy from local tumor burden. He was eventually admitted to the hospital for pain control, where he elected to proceed with an epidural trial prior to intrathecal pump implantation. An epidural catheter was placed at the L3-4. A solution containing 40 mcg/mL morphine, 0.025% bupivacaine, and 2.5 mcg/mL clonidine was infused at a rate of 6 mL/hour. With successful pain control on this regimen, the patient elected to proceed with intrathecal pump implantation.
Case 6
A sixty-nine-year-old female with a remote history of breast cancer and recent diagnosis of thyroid cancer presented with a metastatic lesion in the sacrum. She had low back pain with radicular pain of the right thigh along the S1 and S2 distribution. The neuropathic pain was the predominant complaint. Patient did not tolerate opioids (oxycodone extended-release 20 mg three times a day and hydromorphone 4 mg as needed) because they caused side effects of sedation without pain relief. The pain did not improve with radiation therapy 35 Gy and sacroplasty. Patient initially underwent caudal epidural steroid injection with transient relief (four days). Patient then underwent dorsal column stimulator trial with good low back and right leg coverage. Implant was performed with percutaneous leads (Medtronics RestoreSensor SureScan MRI), and patient currently has discontinued opioids, ambulating, with full coverage of her pain ( Figure 6A ).
Technique

Ultrasound-Guided Sacroiliac Joint Injection
Under sterile precautions, a 2-5 MHz curvilinear array ultrasound probe (GE LogicE P9) was positioned to the junction of the distal PSIS and sacrum. After adequate skin anesthesia, under continuous ultrasound guidance, a 25-gauge two-inch needle was placed into the sacroiliac joint at the level of the S2 foramen. After negative aspiration, a mixture of 3 mL 0.25% bupivacaine and 40 mg Kenolog was injected under ultrasound visualization (Figure 7 ).
Lateral Branch Diagnostic Block
The right sacral iliac joint was located under anteriorposterior and oblique views using fluoroscopy. A 20-gauge five-inch needle was advanced to the superior midline of the L5 transverse process. After bony contact and negative aspiration for heme, 0.5 mL 0.25% of bupivacaine was injected. While remaining engaged in the original insertion site, the needle was withdrawn, repositioned, and advanced toward the right sacral ala, the lateral border of the S1 foramen (at the 3 and 5 o'clock position), the lateral border of the S2 foramen (at the 3 and 5 o'clock), and at the lateral border of the S3 foramen (at 3 o'clock). At each location, bony contact and negative aspiration for heme was done prior to injecting 0.5 mL 0.25% of bupivacaine.
Radiofrequency Ablation of Lateral Branches
The RFA procedure was similar to the block technique, except the needle placed was a 100 mm 22-gauge RF needle with a curved 10 mm active tip. For each level, sensory stimulation was accepted at 1 mV or less (2 Hz, 50 ms), while motor stimulation was negative (or back musculature only) up to 2.5 mV. After positive stimulation at the L4 and L5 lateral branch block (LBB), 0.5 mL of 0.25% bupivacaine was given. Subsequently, a thermal lesion of 80 C for 90 seconds was performed. The needle was redirected to the lateral border of S1, S2, and S3 at multiple locations around each foramen. At the second position at each foraminal level, it was possible that stimulation was not achieved under 1 mV (especially after local anesthetic was given). Thus, if motor stimulation was negative and position of the needle was verified in AP and lateral view, the lesion was conducted.
Kyphoplasty-Sacroplasty
After induction of general anesthesia with the patient in the prone position on the fluoroscopy table, under sterile conditions 10-gauge kyphoplasty guide needles were advanced into the right sacral ala utilizing CT fluoroscopy. A 10 mm bone tamp was advanced coaxially into the S2 segment of the sacrum. This was inflated to a volume of 1 mL with a PSI of 250. Under intermittent Carm fluoroscopy, high-viscosity radiopaque PMMA containing hydroxyapatite (ActivOs) was infused into the right sacral ala. A total of 3.6 mL of the PMMA was infused into the right sacral ala. Fluoroscopic imaging revealed adequate infiltration of the PMMA into the right sacral ala fracture. No significant foraminal or extraosseous extravasation was encountered. Postprocedure CT scan demonstrated adequate sacral augmentation ( Figure 4B ). We acknowledge that other techniques are described in the literature with solely fluoroscopic, CT, or navigation imaging modalities, which may be appropriate to use in this population [8] .
Intrathecal Pump Placement
After induction of general anesthesia, with the patient in the right lateral decubitus position on the OR table, fluoroscopy was used to identify the L3-4 vertebral level, Figure 6 (A) Axial cut T2 weighted MRI image of the sacrum at the S1 foramen. Patient has black areas of the right sacrum denoting sacroplasty and invasion of the right sacrum with tumor after radiation changes, and (*) denotes enlarged S1 nerve root consistent with a swollen or inflamed nerve. (B) Dorsal column stimulation leads placed at T7. Two leads in staggered formation to cover both low back pain and right posterior thigh pain. entry level for the spinal needle once CSF was aspirated. The intrathecal catheter was then advanced until the tip was just superior to the L1 superior vertebral endplate as noted on fluoroscopy. The pump was then secured within a pouch to the subcutaneous pocket. Upon emergence from anesthesia, the patient was neurologically intact, and his intrathecal pump initiated using a solution containing morphine 6 mg/mL, bupivacaine 25 mg/mL, and clonidine 200 mcg/mL at a rate of morphine 1.2 mg/day, bupivacaine 5 mg/day, and clonidine 40 mcg/day.
Dorsal Column Stimulator Placement
Trial lead was performed with patient in prone position with MAC anesthesia. Under fluoroscopic guidance, one dorsal column lead was placed at T7 midline posterior epidural space. Once trial was successful for three days and patient noted 60% pain relief, the patient underwent permanent percutaneous placement of the dorsal column stimulator. Initial lead was placed at T7 midline; however, a second lead was placed right of midline slightly below the first lead ( Figure 6B ). The leads were attached to a Medtronics RestoreSensor SureScan MRI battery, and the patient tolerated the settings of 460 Hz and pulse width 510 microseconds as the primary program.
Results
There were no complications during the above procedures.
Case 1: Patient had immediate improvement in his bilateral buttock pain. He was able to stand and walk without clinically significant discomfort. His NRS pain score was 2-3/10, and he was able to resume his ADLs without requiring assistance. Eleven months after his procedure, he reports continued pain relief, requiring no pain medication since his procedure while tolerating chemotherapy.
Case 2: Patient had marked improvement in right low back, right hip, and leg pain. The patient was able to stand without much discomfort and was able to sleep comfortably through the night. His postprocedure NRS pain score improved to 0-4/10, depending on activity. The patient experienced four months of relief with satisfactory return of his activities of daily living. Unfortunately, due to progression of disease, he required a subsequent RFA of the lateral branches that provided an additional one month of relief prior to his passing away.
Case 3: Patient's NRS pain score improved to 0-4/ 10. He reduced his NSAIDs significantly, and this pain relief continued for five months. Unfortunately, thereafter his disease progressed, invading further into his ileum to include his acetabulum and sciatic nerve. He underwent orthopaedic debulking surgery for this metastasis but subsequently passed away shortly thereafter.
Case 4: Patient's NRS pain score improved to 0-2/10 within 24 hours post-sacral augmentation therapy. He remained on pregabalin for preexisting cervical neuralgia but was able to stop all NSAIDs and diazepam. His pain relief remained throughout five months of follow-up, at which time the patient discharged himself from our clinic. In the six months since that time, his physical therapy notes indicate continued pain relief and preserved function.
Case 5: Over the remainder of his postoperative recovery, his intrathecal pump dosing was titrated to effect. On the day of discharge, he was receiving morphine 1.45 mg/day, bupivacaine 6 mg/day, and clonidine 48.3 mcg/day. Additionally, the PTM bolus function was enabled at a dose of morphine 0.12 mg, bupivacaine 0.5 mg, and clonidine 4 mcg with a lockout of two hours, maximum 12 doses/day. His NRS pain score at discharge was 4/10. For nearly 15 months postprocedure, the patient's left-sided sacroiliac and leg pain was well controlled with occasional small adjustments to his pump dosing. Unfortunately, thereafter his disease progressed rapidly with multisystem sequelae, and in the last three months of life he required multiple hospital admissions for pain control prior to passing away. Of note, prior to his death, the IT pump had been titrated to an eventual dosing of morphine 14 mg/day, bupivacaine 14 mg/day, and clonidine 305 mcg/day; PTM settings were morphine 1 mg, bupivacaine 1 mg, and clonidine 22 mcg with a two-hour lockout and max 12 doses/day. Case 6: Patient postprocedure was ambulating, walking without pain, in great spirits. One month postprocedure, she was weaned off all opioids and has gained five pounds because her appetite returned. She continues to have good pain relief and requires no opioids for pain control. She continues to alternate her settings for different daily functions, but primarily using higher-frequency settings of 460 or 430 Hz. At these settings, the patient does not feel paresthesia, rather a numbness sensation along her low back and posterior thighs bilaterally.
An assessment of 25 patients with sacroiliac disease including the six discussed cases is presented in Table 1 . Each patient was managed with our developed paradigm, and described is the last resulting procedure performed for improved pain control. In 13 of 25 patients, sacroiliac joint injection was sufficient to manage a patient's pain. In all cases, opioid medications were successfully reduced.
Discussion
This case series illustrates the use of various interventional pain management techniques to treat bony metastatic pain affecting the sacrum and ilium.
Based on our experience treating these patients, we recommend a treatment algorithm as illustrated in Figure 8 . The most important factors to consider when choosing between interventional pain management techniques include tumor location, invasion of the SI joint space, presence of insufficiency fracture, and neural foraminal compromise. If the SI joint has tumor invasion that destroys the actual joint space, it is unlikely the joint is accessible for a joint injection. Thus the algorithm distinctly changes if joint space is visualized on imaging, with direct tumor invasion leading to a decision of forgoing a joint injection. Furthermore, we feel that if foraminal disease is present, should a steroid injection not provide long-lasting pain relief, an intrathecal drug delivery system or neurostimulation may be an effective alternative pain treatment choice.
For most patients either an intra-articular sacroiliac joint steroid injection or diagnostic LBB can be performed first [5] . These procedures are relatively easy to perform, and we have seen long-lasting improvement of sacroiliac tumor-related pain after a single steroid injection. In addition, these procedures can be performed using ultrasound in lieu of fluoroscopy. This alternate imaging modality is especially useful when patients are unable to tolerate the prone position necessary for fluoroscopic guidance.
The innervation of the sacroiliac joint is somewhat controversial and relates mostly to only the posterior aspect of the sacrum. While most experts agree that the sacroiliac joint is innervated by the lateral branches of the S1-S3 dorsal rami and the L5 dorsal ramus, there are reported variations that include contributions from the dorsal rami of L3, L4, and S4 [7] . More recently, cadaveric studies support the majority of innervation from S1 to S3, with less than 10% of cadavers demonstrating innervation from L5 and S4 [9] . The neuroanatomy supplying the anterior sacrum is less clear and may be more complex. For example, Bogduk has theorized that branches of the lumbar plexus as high as L2 may help to innervate the anterior sacrum [10] . The broad distribution of innervation helps to explain why pain referral patterns originating from the sacroiliac joint presents are frequently heterogeneous and variable. It is also because of these neuroanatomic variations that individuals respond differently to RFA procedures [7] . A complete understanding of the sacral anatomy may elucidate further targets for pain control [11] .
In our patients, we target the medial branches of L4 and L5 and the lateral branches from S1 to S3 in order to cover the pain fibers stemming from not only the joint but also the posterior surface of the sacrum and/or ilium in addition to the periosteum. We choose a single insertion technique, which seems to be easier to tolerate without anesthesia. We do acknowledge that this technique may lead to incomplete denervation of the lateral sacrum. As with lumbar medial branch ablation, neurotomy has the best chance of success when the radiofrequency needle is placed parallel to the sacrum [12] . Secondary to anatomic considerations, it is difficult to place conventional radiofrequency needles in this orientation, except at the L5 dorsal ramus and the lateral branch of S3. It is conceivable that we may lack the optimal contact at some of the lumbar and sacral branches innervating the sacrum and sacroiliac joint, but this may be true of all known techniques described in the literature [13, 14] .
In oncologic patients, sacroiliac joint dysfunction may only contribute partially to sacral and gluteal pain. Periosteal inflammation frequently results from tumor invasion and may involve the iliolumbar ligament spanning from the iliac crest to L5. Inflammation or damage to this ligament may result in referred pain affecting the hip, pelvis, groin, or back. Tumors near the posterior superior iliac spine (PSIS) may also irritate or exert mass effect on the cluneal nerves [15] , which branch off the lumbar spinal nerves and are located only 5 to 7 cm Table 1 Patients undergoing the paradigm treatment plan for sacroiliac joint pain and the resulting pain relief and opioid medication reduction away. Patients may present with lateral and superior gluteal pain [16] . We recommend blocking the superior cluneal nerves if pain does not improve with more conventional interventional measures and the patient has metastatic disease affecting the iliac crest.
It is important to note that the neurolytic techniques described above should be used in conjunction with oncologic therapy. Bone-strengthening agents, systemic chemotherapy, radiation, and surgical interventions may all help to reduce tumor load and/or improve pain. A variety of minimally invasive techniques have been described for palliation of sacral metastatic disease [17, 18] . These include cryosurgery, radiosurgery, and the use of high-intensity focused ultrasound (HIFU) [17, 18] . Surgical techniques range from bone curettage to compression and sacral reconstruction [19, 17, 18] . Trumm et al. describe a case report where a patient with intolerable low back pain secondary to tumor invasion of the sacroiliac joint benefited from stabilization using a combination of iliosacral screw placement and osteoplasty [20] . Usually destruction of the sacrum Figure 8 Flow chart of interventional procedures based on tumor location and improvement in pain control for patients with sacroiliac joint metastasis. SI ¼ sacroiliac.
precludes useful hardware anchoring; however, if necessary long constructs that connect the pelvis to the lumbar spine may be utilized. Patients who are already weakened from cancer may not tolerate these procedures due to long exposure and healing times.
Radiotherapy has been shown to improve pain and reduce the number of skeletal related events in patients with metastatic bony disease [21] . Analgesia after radiotherapy is thought not only to result from tumor size reduction, but also to be secondary to reduction of inflammatory cells and their chemical pain mediators [21] . We have found that patients with tumor-related sacroiliac pain scheduled for radiation therapy will often better tolerate the process after at least partial denervation of the painful area to be irradiated. These points are illustrated in our pain treatment paradigm.
In the two cases where the lateral branch nerves were successfully ablated (Case 2 and Case 3), one patient had lytic lesions whereas the other had blastic lesions. We have found that, regardless of tumor type, denervation of the joint has a reasonable chance of pain improvement if the sacral periosteum is intact (which can be assessed by CT imaging) [23] [24] [25] . Disruption of the periosteum may distort the anatomy such that locating the lateral branches may be difficult. This is reflected in our paradigm showing that patients with periosteal destruction may be better treated with sacroplasty or intrathecal drug delivery. It is important to note the risks associated with sacroplasty in this population. While fracture extension into the foramen has not served as an absolute contraindication to sacroplasty at our institution, patients with such fractures require very careful observation of the cement fill during the procedure in order to prevent symptomatic nerve root compression [22] .
We also illustrate a case in which spinal cord stimulation was successful in managing a patient's sacral and associated radicular pain. We have found dorsal column stimulation especially helpful when pain symptoms are primarily neuropathic and radicular in nature. Newer stimulator technologies offer higher-frequency settings that reportedly provide superior and paresthesia-free coverage of the pain distribution and should be further evaluated in the oncologic population. A trial of caudal or lumbar epidural steroid injection for temporizing pain is also common in our practice and reasonable for those patients presenting with radicular symptoms. In some patients with severe pain, we have even placed an epidural catheter to be used for analgesic infusions during radiation treatment sessions. Caution should be used for intrathecal or epidural catheters placed near the sacral nerve roots as in our experience these patients are prone to urinary/fecal symptoms (retention or incontinence) and/or lower extremity paresthesias.
Each clinical case is unique, and it is useful to address goals of care as a comprehensive treatment team. In our institution, a spine tumor board consisting of radiation oncologists, oncologic surgeons, interventional radiologists, rehabilitation specialists, and interventional pain physicians meets weekly to discuss complicated cases. Many innovative therapeutic ideas and research projects have resulted from these multidisciplinary discussions, and we highly recommend forming such comprehensive patient care teams at other institutions.
Conclusion
We present a case series and interventional therapeutic paradigm illustrating pain treatment options for patients suffering from sacroiliac metastatic disease. Often pain symptoms can mimic sacroiliitis or lumbosacral radiculopathy. Factors to consider when deciding between pain control options include tumor location, invasion of the SI joint space, and presence of insufficiency fracture, neural foraminal compromise, and patient preference. In our case series, all patients had improvement of pain symptoms and required less opioid medication after using our proposed treatment algorithm. While further prospective research is warranted, this case series can be used as a preliminary guide to manage sacral pain in oncologic patients suffering from sacral metastatic disease.
